Vera Therapeutics, Inc. 4

President and CEO Fordyce Marshall exercised 18,500 options and sold 18,500 Vera Therapeutics Class A shares on May 12, 2026 under a Rule 10b5-1 plan.

On May 12, 2026, Vera Therapeutics, Inc. President and CEO Fordyce Marshall exercised 18,500 stock options at an exercise price of approximately $2.90 per share, acquiring 18,500 shares of Class A Common Stock, and then sold a total of 18,500 shares of Class A Common Stock in two Rule 10b5-1(c) pre-planned transactions at weighted-average prices of $36.64 and $37.09 per share. The gross value of shares acquired via option exercise was roughly $53,600, while the gross proceeds from the associated sales were approximately $677,800, representing a classic exercise-and-sell transaction, after which he beneficially owned 235,244 shares directly. This amended Form 4 was filed to correctly reflect the option exercise and to adjust the reported post-transaction beneficial ownership amounts.

Filing Facts

CIK

1831828

Ticker

VERA

Form

4

Source Type

fda

Accession

0001859453-26-000011

Alert Tier

6